Studying TRYPTYR to Improve Quality of Life and Work Ability in Adults with Dry Eye Disease

What this Trial Is About

Dry eye disease DED is a common condition that affects both working-age adults and the elderly, causing symptoms like dryness and burning, and signs such as decreased tear production or increased tear evaporation. Diagnosing and treating DED can be challenging because symptoms and signs do not always match. This research aims to study a new treatment called Acoltremon 0.003% TRYPTYR, recently approved by the FDA, to see if it can improve the quality of life and work ability of people suffering from DED by stimulating tear production through activating specific nerve receptors. Participants who qualify will receive TRYPTYR during the 1-month study, which includes three visits. TRYPTYR acts as a TRPM8 receptor agonist that stimulates cold thermoreceptors on the eyes nerves to increase tear production. The study focuses on assessing the effect of this medication on patients experiencing dry eye symptoms, with dosing and administration details provided during the visits. During the study, adults aged 18 to 75 years with diagnosed DED lasting at least six months and currently symptomatic will be assessed through visual analog scales, tear tests, and quality of life questionnaires related to work. Researchers will monitor changes in work-related quality of life scores at 14 and 28 days. Participants will also undergo eye exams, vision tests, and symptom assessments to track safety and treatment effects throughout the study.

Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work